Three-in-One Stop Computed Topography Angiography(CTA) and CT Perfusion(CTP) in Cerebrovascular Disease

NCT06890468 | Not Yet Recruiting

• 1 other identifier: 301-CTAP
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This research takes patients with cerebrovascular diseases as the research subjects and employs the experimental design of a prospective cohort study, aiming to innovatively develop and validate a "one-stop" multimodal CT examination scheme. The 301-CTAP multimodal CT technique implies that three modalities are acquired through a single collection, including head and neck CTA (head and neck CTA), multiphase CTA imaging of the brain (multiphase CTA), and CT perfusion imaging of the brain (CT perfusion).

Conditions

Radiology; Vascular Diseases

Keywords

CTP; head and neck CTA

Outcome Measures

Primary Outcomes (1)

• Three-in-One Stop Computed Topography Angiography and Perfusion（301-CTAP） in the diagnosis of cerebrovascular disease performance description

  Three-in-One Stop computed topography angiography and computed topography perfusion in cerebrovascular disease performance, including lesions in the detection and imaging in the diagnosis of image quality, accuracy, sensitivity and specificity.

  2 years

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with cerebrovascular disease

You may qualify if:

• Age≥18 \<100years
• Head and neck artery stenosis/occlusion, moyamoya disease, aneurysm, artery dissection, etc., may include patients with acute stroke, chronic cerebral ischemia, and asymptomatic patients. After clinical assessment, CT perfusion imaging is required
• The image quality meets the requirements of diagnosis and post-processing
• Patients who follow the scanning strategy to complete the examination
• The patient or his or her family agrees to provide clinical data and follow-up
• Patients or their families sign informed consent forms

You may not qualify if:

• \< 18 years old
• People who are allergic to iodine contrast agents, or who cannot be tested temporarily due to taking metformin or aminoglycoside drugs
• Renal failure patient
• Severe cardiac insufficiency
• Severe liver damage
• Patients with an expected survival of less than 1 year
• Patients with cerebrovascular diseasePregnant woman

Sponsors & Collaborators

• Xin Lou: lead

Study Sites (1)

Chinese PLA General Hospital, Beijing, Beijing 100853

Beijing, China

Location

MeSH Terms

Conditions

Vascular Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Officials

• Xin Lou

  Chinese PLA General Hospital

  STUDY CHAIR

Central Study Contacts

xiaoxuan Ma

CONTACT

+8613681126807; xiaoxuan5686@126.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chairman

Study Record Dates

• First Submitted: March 15, 2025
• First Posted: March 24, 2025
• Study Start: March 16, 2025
• Primary Completion (Estimated): December 30, 2029
• Study Completion (Estimated): December 30, 2029
• Last Updated: March 24, 2025

Record last verified: 2025-03

Locations

CN (1)